By: IPP Bureau
Last updated : November 18, 2025 12:49 pm
This move positions the U.S.-based consumer healthcare company for a significantly larger role in the rapidly expanding at-home and retail diagnostic testing market
Kingsway Pharmaceuticals, a leading US-based consumer healthcare company known for its nationally distributed over-the-counter brands and private-label solutions, has announced a strategic minority investment in CIGA Healthcare, a global innovator in rapid tests and home diagnostics serving over 70 countries.
This move positions the U.S.-based consumer healthcare company for a significantly larger role in the rapidly expanding at-home and retail diagnostic testing market.
"Families deserve confidence, clarity, and access when it comes to their health. For us, this is more than expansion—it’s stewardship,” said Benjamin Blessing, COO of Kingsway Pharmaceuticals. “By partnering with CIGA Healthcare, we are securing a faster, more stable supply path for diagnostics in the U.S. and expanding the innovation we can deliver to retailers and consumers. Diagnostics empower households to make informed health decisions at home, and we are committed to leading in that space with integrity and impact.”
The partnership positions Kingsway to tap into CIGA Healthcare’s global manufacturing and technology capabilities while leveraging its own deep knowledge of the US retail landscape and consumer brand-building expertise. This combination is expected to accelerate the availability of rapid and home-based diagnostic solutions, particularly as demand for accessible, reliable healthcare tools continues to grow.
Irwin Armstrong, CEO of CIGA Healthcare, highlighted the complementary strengths of the alliance. “We are delighted to partner with Kingsway Pharmaceuticals. Their U.S. market expertise, retail relationships, and consumer-focused approach perfectly complement our global diagnostics platform. Together, we will expand access to diagnostic testing across new categories, markets, and channels.”
The partnership is expected to roll out enhanced diagnostic offerings in major US retail chains over the coming months, marking a significant step forward for both companies in redefining how consumers engage with home healthcare and diagnostics.